RIGI and viral infectious disease: PRMT7 attenuates the binding of MAVS to TRIM31 and RIG-I by catalyzing the mono-methylation of MAVS at the R52 residue, but aggregated PRMT7 is incapacitated upon viral infection due to auto-methylation at the R32 residue, subsequently alleviating its suppressive effect on MAVS activation [69].